Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus.
about
Nebuliser systems for drug delivery in cystic fibrosisInhaled therapy in cystic fibrosis: agents, devices and regimensColistimethate sodium for the treatment of chronic pulmonary infection in cystic fibrosis: an evidence-based review of its place in therapyInhalable Antimicrobials for Treatment of Bacterial Biofilm-Associated Sinusitis in Cystic Fibrosis Patients: Challenges and Drug Delivery Approaches.PEI-engineered respirable particles delivering a decoy oligonucleotide to NF-κB: inhibiting MUC2 expression in LPS-stimulated airway epithelial cellsThe role of disposable inhalers in pulmonary drug delivery.Clinical experimentation with aerosol antibiotics: current and future methods of administration.Inhaled antibiotics for lower airway infections.Pulmonary function parameters and use of bronchodilators in patients with cystic fibrosis.Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosisA first-year dornase alfa treatment impact on clinical parameters of patients with cystic fibrosis: the Brazilian cystic fibrosis multicenter studyPharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.The expanding role of aerosols in systemic drug delivery, gene therapy and vaccination: an update.Sub-inhibitory concentrations of some antibiotics can drive diversification of Pseudomonas aeruginosa populations in artificial sputum mediumIn-vitro and in-vivo evaluation of ciprofloxacin liposomes for pulmonary administration.Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis.Mucoactive agents for chronic, non-cystic fibrosis lung disease: A systematic review and meta-analysis.Ciprofloxacin DPI: a randomised, placebo-controlled, phase IIb efficacy and safety study on cystic fibrosis.Polymorphisms in ADRB2 gene can modulate the response to bronchodilators and the severity of cystic fibrosis.Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study.Physiotherapy for cystic fibrosis in Australia and New Zealand: A clinical practice guidelineAccurate reporting of adherence to inhaled therapies in adults with cystic fibrosis: methods to calculate "normative adherence".Early eradication of Pseudomonas aeruginosa in patients with cystic fibrosis.Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine.Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery.Inhaled mannitol for the treatment of cystic fibrosis.Phenotypes selected during chronic lung infection in cystic fibrosis patients: implications for the treatment of Pseudomonas aeruginosa biofilm infections.Inhaled aztreonam lysine for cystic fibrosis pulmonary disease-related outcomes.Engineered PLGA nano- and micro-carriers for pulmonary delivery: challenges and promises.Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials.Tobramycin inhalation powder: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.Colistimethate sodium dry powder for inhalation: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.Enhancing adherence to inhaled therapies in cystic fibrosis.Tobramycin inhalation powder: an efficient and efficacious therapy for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis.Pulmonary drug delivery: a review on nanocarriers for antibacterial chemotherapy.Bronchodilators in cystic fibrosis: a critical analysis.Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence.New perspectives in nanotherapeutics for chronic respiratory diseases.Synthesis and Characterization of Nanocomposite Microparticles (nCmP) for the Treatment of Cystic Fibrosis-Related InfectionsDevelopment of a microparticle-based dry powder inhalation formulation of ciprofloxacin hydrochloride applying the quality by design approach.
P2860
Q24197879-315B6D59-A1D4-44E7-B6BC-C1736FDA28F9Q26797450-88C39882-2F4F-4D37-B7AC-511745C176A9Q27014993-7087AA7C-EF7F-4EA9-A18C-16C91884C130Q28077482-4DB0C747-FFA2-4309-B452-28E114B4583BQ28484221-544B7DC2-A845-4B5B-9592-F5DBAE1B16F3Q30368417-228734A0-5F5C-468D-AE19-87189F06418FQ30448377-D265FD84-2D39-4180-823C-E1D4480E2135Q33640488-D2C51DF7-3EBA-46E5-BF62-E5FCA86BFF67Q33823882-B3558B34-8A3B-4EB7-B07D-19C4351D941FQ33862073-37D216BF-4374-4CBE-9B00-D7C1744D223CQ34279583-B4EFCE8B-E1BE-431E-A1F7-FE6C40E371F0Q34297656-EC6709EC-9F96-4C24-B93C-8C2715B64DA8Q34433909-740593C8-EEB5-4579-A810-BFD98C2AD62BQ34860393-94ACCB4E-83ED-4931-9914-EE8C518F85D8Q35046837-B46B1952-59FB-4B27-9FE9-919B6C1EAEE1Q36288672-7AB080BC-7E53-429D-AECE-484A96161AA0Q36343003-D743BB8F-4884-4913-A296-F759660DC695Q36374382-BFC7D2A1-7E35-45ED-A128-D4FA885FF805Q36572022-2D40442A-9C0D-4837-8A26-DCD613D966FFQ36677316-787B6F75-CE2C-4A95-ABD6-362A1DF2FACBQ36824415-805ED662-C262-422A-A203-D21A8D411ACBQ36944153-2A85D10F-5DFB-48ED-BA26-2C6A628F8DA1Q37727308-1BA4E863-72DE-40C8-AEDB-17C330D2DAFCQ37738904-6A334DD7-35D3-4AE4-B40A-C82CDDDA7086Q37978509-1C9E88E9-6B8C-4155-BAB2-0EC8C3D9EC20Q37979246-BC44B1C6-3741-46CF-9F7A-F7EA483B7283Q38006032-A1032551-DCC3-43D8-854E-92AB804FE3ACQ38024091-8747622D-0D8B-463E-8616-236627362318Q38033610-E152EE43-980B-4EF7-B5E8-B00E4C00EC7CQ38099053-03815526-F453-4CAA-8B85-A408888046FEQ38160206-0A8189AE-E00D-42EA-95C3-49F598E96305Q38186636-860F60EB-E163-4F2E-AAC7-93FE141B876CQ38193291-BF210AE4-3324-4159-9C22-BEB9AFFDDFCBQ38358856-BA4DCD7C-30F9-4C8C-A40F-FE1AEF6DD0C9Q38552573-32A3D290-61B5-4452-B3D6-071674E313AAQ38975700-CBAE02DF-E507-480E-9D9C-930335244B38Q39282311-3DA1DBDE-685D-4786-8936-B9DB5D9F8B85Q40039105-5CA794E5-9CB0-49FE-A86A-1FD9CC49EB97Q40709327-7E1F9256-D9E9-4532-9555-90FDC2B45883Q41478492-65F52470-178C-4442-BD97-F4D93EC1398E
P2860
Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Inhaled medication and inhalat ...... ibrosis: A European consensus.
@ast
Inhaled medication and inhalat ...... ibrosis: A European consensus.
@en
Inhaled medication and inhalat ...... ibrosis: A European consensus.
@nl
type
label
Inhaled medication and inhalat ...... ibrosis: A European consensus.
@ast
Inhaled medication and inhalat ...... ibrosis: A European consensus.
@en
Inhaled medication and inhalat ...... ibrosis: A European consensus.
@nl
prefLabel
Inhaled medication and inhalat ...... ibrosis: A European consensus.
@ast
Inhaled medication and inhalat ...... ibrosis: A European consensus.
@en
Inhaled medication and inhalat ...... ibrosis: A European consensus.
@nl
P2093
P1476
Inhaled medication and inhalat ...... ibrosis: A European consensus.
@en
P2093
Elsbeth Westerman
Gerd Döring
Harry Heijerman
Steven Conway
consensus working group
P304
P356
10.1016/J.JCF.2009.04.005
P577
2009-06-25T00:00:00Z